Abstract:Objective Pancreatic cancer is one of the most lethal human malignancies. Gemcitabine is widely used to treat pancreatic cancer, and the resistance to chemotherapy is the major difficulty in treating the disease. N 6 -methyladenosine (m 6 A) modification, which regulates RNA splicing, stability, translocation, and translation, plays critical roles in cancer physiological and pathological processes. METTL14, an m6A Lmethyltransferase, was found deregulated in multiple cancer types. However, its role in gemcitabine resistance in pancreatic cancer remains elusive. Methods The mRNA and protein level of m 6 A modification associated genes were assessed by QRT-PCR and western blotting. Then, gemcitabine‐resistant pancreatic cancer cells were established. The growth of pancreatic cancer cells were analyzed using CCK8 assay and colony formation assay. METTL14 was depleted by using shRNA. The binding of p65 on METTL14 promoter was assessed by chromatin immunoprecipitation (ChIP) assay. Protein level of deoxycytidine kinase (DCK) and cytidine deaminase (CDA) was evaluated by western blotting. In vivo experiments were conducted to further confirm the critical role of METTL14 in gemcitabine resistance. Results We found that gemcitabine treatment significantly increased the expression of m 6 A methyltransferase METTL14, and METTL14 was up-regulated in gemcitabine-resistance human pancreatic cancer cells. Suppression of METTL14 obviously increased the sensitivity of gemcitabine in resistant cells. Moreover, we identified that transcriptional factor p65 targeted the promoter region of METTL14 and up-regulated its expression, which then increased the expression of cytidine deaminase (CDA), an enzyme inactivates gemcitabine. Furthermore, in vivo experiment showed that depletion of METTL14 rescue the response of resistance cell to gemcitabine in a xenograft model. Conclusion Our study suggested that METTL14 is a potential target for chemotherapy resistance in pancreatic cancer.

m6A eraser FTO impairs gemcitabine resistance in pancreatic cancer through influencing NEDD4 mRNA stability by regulating the PTEN/PI3K/AKT pathway

Additional File 14 of M6a Eraser FTO Impairs Gemcitabine Resistance in Pancreatic Cancer Through Influencing NEDD4 Mrna Stability by Regulating the PTEN/PI3K/AKT Pathway

N6-methyladenosine modification of FZR1 mRNA promotes gemcitabine resistance in pancreatic cancer

Data from N6-methyladenosine Modification of FZR1 Mrna Promotes Gemcitabine Resistance in Pancreatic Cancer

N 6-Methyladenosine Modification of FZR1 Mrna Promotes Gemcitabine Resistance in Pancreatic Cancer.

ZC3H13-mediated N6-methyladenosine modification of <i>PHF10</i> is impaired by fisetin which inhibits the DNA damage response in pancreatic cancer

m6A Methyltransferase METTL14-Mediated Upregulation of Cytidine Deaminase Promoting Gemcitabine Resistance in Pancreatic Cancer

M6 A demethylase fat mass and obesity-associated protein regulates cisplatin resistance of gastric cancer by modulating autophagy activation through ULK1

RNA N6-methyladenosine demethylase FTO promotes pancreatic cancer progression by inducing the autocrine activity of PDGFC in an m6A-YTHDF2-dependent manner

M(6)A demethylase fat mass and obesity-associated protein regulates cisplatin resistance of gastric cancer by modulating autophagy activation through ULK1

The Role of the Fat Mass and Obesity-Associated Protein in the Proliferation of Pancreatic Cancer Cells

M6a RNA Demethylase FTO Promotes the Growth, Migration and Invasion of Pancreatic Cancer Cells Through Inhibiting TFPI-2

N6-methyladenosine modified TGFB2 triggers lipid metabolism reprogramming to confer pancreatic ductal adenocarcinoma gemcitabine resistance

FTO Regulates the Chemo‐radiotherapy Resistance of Cervical Squamous Cell Carcinoma (CSCC) by Targeting Β‐catenin Through Mrna Demethylation

m6A demethylase FTO promotes tumor progression via regulation of lipid metabolism in esophageal cancer

Research advances of N6‐methyladenosine in diagnosis and therapy of pancreatic cancer

FTO facilitates cancer metastasis by modifying the m6A level of FAP to induce integrin/FAK signaling in non-small cell lung cancer

N6-Methylation of Adenosine of FZD10 Mrna Contributes to PARP Inhibitor Resistance.

FTO-mediated cytoplasmic m6Am demethylation adjusts stem-like properties in colorectal cancer cell

Epigenetic Activation of the CMTM6‐IGF2BP1‐EP300 Positive Feedback Loop Drives Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma

m6A demethylase ALKBH5 inhibits pancreatic cancer tumorigenesis by decreasing WIF-1 RNA methylation and mediating Wnt signaling